Foundayo vs Zepbound: How the Pill and the Shot Compare
Foundayo vs Zepbound compared from the FDA labels: the daily orforglipron pill and the weekly tirzepatide shot on weight loss in separate trials, side effects, dosing, switching, and cost.
Foundayo vs Zepbound comes down to a daily pill versus a weekly shot. Foundayo (orforglipron) is a once-daily GLP-1 tablet the FDA approved on April 1, 2026. Zepbound (tirzepatide) is a once-weekly injection that acts on two hormone receptors, GIP and GLP-1. In separate trials, Zepbound produced larger average weight loss, but we found no trial that compared the two directly.
Both medicines come from Eli Lilly, and both mostly cause stomach and gut side effects. For the full list on the shot, see our page on Zepbound side effects.
Key takeaways:
- Different molecules. Foundayo is not a Zepbound pill. It is a small-molecule GLP-1 drug; Zepbound is a dual GIP and GLP-1 peptide.
- Different results. At the top doses, average 72-week weight loss was 11.1% with Foundayo and 20.9% with Zepbound, in separate trials.
- Different routines. Foundayo is one tablet a day with or without food. Zepbound is one injection a week.
- Different prices. Lilly's self-pay price starts at $149 a month for the lowest Foundayo dose and $299 for Zepbound 2.5 mg, and both cost more at higher doses.
Table of Contents
- Foundayo vs Zepbound at a Glance
- Is Foundayo a Zepbound Pill?
- How Foundayo and Zepbound Work
- Which Causes More Weight Loss?
- Switching From Zepbound to Foundayo
- How You Take Each One
- Foundayo vs Zepbound Side Effects
- Warnings That Apply to Both
- Foundayo vs Zepbound Cost and Insurance
- Eating Well on Foundayo or Zepbound
- Which One Might Fit You?
- Frequently Asked Questions
- Conclusion
Foundayo vs Zepbound at a Glance
The Foundayo vs Zepbound choice starts with form and frequency: a tablet every day or a shot every week. The table below pulls the main facts from each FDA label (Foundayo revised 07/2026, Zepbound revised 08/2026). For every approved GLP-1 medicine side by side, see our GLP-1 medications list.
| Feature | Foundayo | Zepbound |
|---|---|---|
| Active ingredient | Orforglipron | Tirzepatide |
| Maker | Eli Lilly | Eli Lilly |
| Form | Tablet taken by mouth | Injection under the skin (pen, KwikPen, or vial) |
| How often | Once daily | Once weekly |
| How it works | GLP-1 receptor agonist (one receptor) | GIP and GLP-1 receptor agonist (two receptors) |
| FDA-approved uses | Weight reduction and long-term maintenance in adults | Weight reduction and long-term maintenance in adults; moderate to severe obstructive sleep apnea in adults with obesity |
| First approved | April 1, 2026 | November 8, 2023 |
| Top-dose weight loss at 72 weeks, no diabetes | 11.1% (17.2 mg) vs 2.1% placebo, ATTAIN-1 | 20.9% (15 mg) vs 3.1% placebo, SURMOUNT-1 |
| Food rules | With or without food | Any time of day, with or without meals |
| Storage | Room temperature | Refrigerator, with limited time at room temperature (rules differ by device) |
| Self-pay starting price | $149 a month, lowest dose | $299 a month, 2.5 mg |
Sources: Foundayo and Zepbound Prescribing Information, Drugs@FDA, and Lilly news releases (prices checked September 24, 2026). Trial results come from separate studies and are not a head-to-head comparison.
Is Foundayo a Zepbound Pill?
No, Foundayo is not a Zepbound pill. Foundayo contains orforglipron, a different molecule from tirzepatide, and we found no FDA-approved tirzepatide pill: the FDA's drug database lists tirzepatide only as injections (Mounjaro and Zepbound).
The mix-up is common: people search for "oral tirzepatide" about 6,200 times a month in the US, according to Ahrefs. Here is what is true as of September 2026:
- Foundayo is orforglipron, approved on April 1, 2026, as a new molecular entity (FDA approval letter, NDA 220934). Its name is pronounced fown-DAY-oh, per its Medication Guide.
- Zepbound and Mounjaro both contain tirzepatide, and both are injections. Mounjaro is the same molecule under a different brand. Our Zepbound vs Mounjaro comparison explains how the two brands differ.
- Compounded products are not FDA approved, the FDA states. A product sold as "tirzepatide tablets" or "oral tirzepatide" is not an FDA-approved medicine. Our page on compounded tirzepatide explains its current legal status.
Foundayo's only approved use is to reduce excess body weight and keep it off long term, together with diet and exercise. It is for adults with obesity, or adults with overweight plus at least one weight-related condition (Foundayo label, section 1).
How Foundayo and Zepbound Work
Foundayo and Zepbound both act on appetite pathways, but in different ways. Foundayo activates one receptor (GLP-1), while Zepbound activates two (GIP and GLP-1), according to each label's section 12.1.
Foundayo is a small, non-peptide molecule taken as a tablet. The label says GLP-1 receptors sit in brain regions that regulate appetite. For what people call "food noise" and what studies show, read food noise. In animal studies, orforglipron reached and activated neurons there. Its half-life is about 29 to 49 hours, so it is taken daily and reaches a steady level after about 1 week.
Zepbound is a peptide based on the GIP hormone sequence, with a molecular weight of 4,813 daltons, and it is given as an injection. A fatty side chain helps it bind to a blood protein, which stretches its half-life to about 5 days. The label says nonclinical studies suggest GIP "may further contribute to the regulation of food intake."
What "dual agonist" means in plain words: Zepbound switches on two gut hormone signals at once. Foundayo switches on one. Both also slow stomach emptying. Both labels say this effect is largest after the first dose and fades over time.
Which Causes More Weight Loss?
Zepbound caused more weight loss than Foundayo in their separate trials. At the top doses, the placebo-adjusted loss was 17.8 percentage points for Zepbound and 9.0 for Foundayo, about twice as much. We found no trial that compared them directly.
Both drugs were tested in 72-week trials in adults without diabetes. ATTAIN-1 enrolled 3,127 people for Foundayo; SURMOUNT-1 enrolled 2,539 for Zepbound. Starting weights were similar (103.2 kg and 104.8 kg).
| Result | Placebo (ATTAIN-1) | Foundayo 5.5 mg | Foundayo 9 mg | Foundayo 17.2 mg | Placebo (SURMOUNT-1) | Zepbound 5 mg | Zepbound 10 mg | Zepbound 15 mg |
|---|---|---|---|---|---|---|---|---|
| Average weight change | -2.1% | -7.4% | -8.3% | -11.1% | -3.1% | -15.0% | -19.5% | -20.9% |
| Difference vs placebo | n/a | -5.3 | -6.2 | -9.0 | n/a | -11.9 | -16.4 | -17.8 |
| Lost at least 10% | 13% | 32.5% | 39.8% | 54.5% | 18.8% | 68.5% | 78.1% | 83.5% |
| Lost at least 15% | 6% | 14.3% | 20.1% | 35.9% | 8.8% | 48.0% | 66.6% | 70.6% |
| Lost at least 20% | 2.9% | 5.9% | 8.9% | 18.4% | 3.1% | 30.0% | 50.1% | 56.7% |
Sources: Foundayo label section 14, Table 6; Zepbound label section 14.1, Table 2.
In adults with type 2 diabetes, the pattern was the same. Foundayo 17.2 mg lowered weight by 9.6% vs 2.5% on placebo (ATTAIN-2). Zepbound 15 mg lowered it by 14.7% vs 3.2% (SURMOUNT-2). Foundayo is not approved to treat diabetes, though it lowered HbA1c by up to 1.7 points in that trial, vs 0.4 on placebo (Foundayo label section 14, Tables 6 and 7; Zepbound label section 14.1, Table 2).
Why this is not a head-to-head result
- No shared trial. In a ClinicalTrials.gov search on September 24, 2026, we found no registered trial that compares orforglipron with tirzepatide.
- Different years. The main 72-week parts ran from 2019 to 2022 (SURMOUNT-1) and 2023 to 2025 (ATTAIN-1).
- Different placebo groups. Placebo weight loss was 3.1% in SURMOUNT-1 and 2.1% in ATTAIN-1.
- Different formulation. The Foundayo trials used an investigational form of orforglipron, reported as equivalent tablet doses (label section 14).
- Same sponsor. Eli Lilly funded both programs.
SURMOUNT-5, a head-to-head weight trial of tirzepatide, compared it with semaglutide (the ingredient in Wegovy), not with Foundayo (Aronne et al., N Engl J Med, 2025). Read our Wegovy vs Zepbound comparison for those results.
Switching From Zepbound to Foundayo
On average, people kept about three quarters of their weight loss after switching from Zepbound to Foundayo in one trial, but some weight came back. In ATTAIN-MAINTAIN, people who moved from tirzepatide to orforglipron kept 74.7% of their lost weight on average at 52 weeks, compared with 49.2% on placebo (among those whose weight had plateaued; 74.4% vs 49.7% across all participants).
The trial, published in Nature Medicine in 2026, enrolled 205 adults from the tirzepatide arm of SURMOUNT-5 who had lost at least 5% of their weight. They were assigned to orforglipron or placebo in a 3:2 ratio. Key numbers:
- Weight path. On orforglipron, average weight went from 90.9 kg at the switch to 95.9 kg a year later, a regain of about 5 kg.
- Strong maintainers. 43.7% kept at least 80% of their loss, vs 16.4% on placebo.
- Large losers. 63.7% of those who had lost at least 15% still had at least 15% off after a year.
The limits matter as much as the headline:
- No arm stayed on Zepbound. The trial cannot say whether switching works as well as continuing the injection. The authors named this as a limitation. Our page on the Zepbound maintenance dose covers what staying on Zepbound or stepping down to 5 mg did in trials.
- Rescue medicine. From week 24, placebo patients who regained at least half their loss could get orforglipron, so the later placebo results are not a pure placebo comparison.
- Short and narrow. It lasted 1 year, ran only at US sites, and enrolled mostly white participants.
The trial used its own switching protocol, which is not a label instruction. The Foundayo label starts treatment at 0.8 mg once daily, and neither label gives instructions for switching between the two, so your prescriber decides how and when to switch. Do not take both together: both labels say combining them with another GLP-1 receptor agonist is not recommended.
How You Take Each One
Foundayo is one tablet by mouth every day, and Zepbound is one injection under the skin every week. Both start low and step up, per section 2 of each label. For every Zepbound dose step in mg, see our tirzepatide dosage chart.
| Detail | Foundayo | Zepbound |
|---|---|---|
| Starting dose | 0.8 mg once daily | 2.5 mg once weekly for 4 weeks (starting dose only) |
| Dose steps | At least 30 days per step: 2.5 mg, then 5.5 mg | At least 4 weeks per step, in 2.5 mg increases |
| Higher doses | 9 mg, 14.5 mg, or 17.2 mg, based on response and tolerability | Maintenance 5, 10, or 15 mg for weight; 10 or 15 mg for sleep apnea |
| Maximum | 17.2 mg once daily | 15 mg once weekly |
| How to take | Swallow whole, with or without food; do not break, crush, or chew | Stomach, thigh, or back of the upper arm (by a helper); rotate sites |
| Missed dose | Take it as soon as possible; never 2 doses in one day. Missed 7 or more days in a row: call your provider about restarting | Take it within 4 days (96 hours); otherwise skip it. Never take 2 doses within 3 days (72 hours) of each other |
| Storage | Room temperature, 68°F to 77°F | Refrigerator. Single-dose pen or vial: up to 86°F for 21 days total. KwikPen or multi-dose vial: refrigerator or room temperature up to 86°F; discard 30 days after first use, after 30 days at room temperature, or after 4 doses |
Sources: Foundayo label sections 2 and 16; Zepbound label sections 2 and 16. Your prescriber sets your dose.
The Foundayo label sets no water amount, fasting period, or time of day. Zepbound comes as a single-dose pen, a multi-dose KwikPen (4 doses), and single-dose and multi-dose vials, and each has its own instructions for use. Storage limits for each form are on our page on Zepbound refrigeration. If you use the multi-dose pen, our Zepbound KwikPen guide walks through each step. For shot technique, see our page on Zepbound injection sites.
Interactions and birth control
Foundayo has more drug interaction rules than Zepbound because the liver enzyme CYP3A4 breaks it down (Foundayo label, section 7):
- Strong CYP3A4 inhibitors: the maximum Foundayo dose is 9 mg, and inhibitors that also block OATP1B, such as ritonavir, should be avoided.
- Strong CYP3A4 inducers: avoid them with Foundayo.
- Simvastatin: do not exceed 20 mg a day with Foundayo.
Both labels share two points. If you use insulin or a sulfonylurea, your prescriber may lower that dose to reduce the risk of low blood sugar. Because both drugs slow stomach emptying, they may affect how other pills are absorbed.
Both labels also address birth control pills. The Foundayo label advises switching to a non-oral method or adding a barrier method for 30 days after starting and after each dose increase. The Zepbound label gives the same advice for 4 weeks.
Foundayo vs Zepbound Side Effects
Foundayo vs Zepbound side effects are mostly the same kind: nausea, vomiting, diarrhea, and constipation, worst while the dose is going up. Vomiting rates look higher with Foundayo, but the label pools come from separate trials and cannot be compared directly.
| Side effect | Foundayo | Foundayo placebo | Zepbound | Zepbound placebo |
|---|---|---|---|---|
| Nausea | 26% to 35% | 10% | 25% to 29% | 8% |
| Vomiting | 13% to 24% | 4% | 8% to 13% | 2% |
| Diarrhea | 21% to 25% | 11% | 19% to 23% | 8% |
| Constipation | 20% to 27% | 9% | 11% to 17% | 5% |
| Hair loss, all users | 4% to 5% | 2% | 4% to 5% | 1% |
| Injection site reactions | Not applicable | n/a | 6% to 8% | 2% |
| Stopped for side effects | 6% to 10% | 3% | 4.8% to 6.7% | 3.4% |
Sources: Foundayo label section 6.1, Table 1 (reactions in at least 5%); Zepbound label section 6.1, Table 1 (reactions in at least 2%).
Other differences in the labels:
- Heart rate. Foundayo raised average heart rate by 4 to 5 beats per minute, vs 0.5 on placebo, and fast heart rate was reported in 3% vs 0.9%. Zepbound raised it by 1 to 3 beats per minute, vs no increase on placebo.
- Low blood pressure. It affected 2% on Foundayo vs 0.5% on placebo, and 1.6% on Zepbound vs 0.1%.
- Severe stomach effects. They affected about 3% on Foundayo and 1.7% to 3.1% on Zepbound, vs 1% on placebo in each program.
Hair loss in women
Hair loss affected women far more than men with both drugs. It was reported in 7% of women on Foundayo (3% on placebo) and 7.1% of women on Zepbound (1.3% on placebo). For men, the rates were under 1% with both drugs. Our page on does Zepbound cause hair loss explains why it happens and whether hair grows back.
For timing, tips, and when symptoms need a call, see the full list of Zepbound side effects.
Warnings That Apply to Both
Foundayo and Zepbound share a boxed warning about thyroid C-cell tumors. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC), or by anyone who has Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), per section 4 of each label.
The warning rests on different evidence. Tirzepatide caused thyroid C-cell tumors in rats. Orforglipron is not pharmacologically active in rats or mice and caused no rodent tumors. The Foundayo label still carries the warning because other GLP-1 drugs that do act in rodents caused these tumors, orforglipron does act on the human GLP-1 receptor, and the relevance of those tumors to humans has not been determined.
Other label points:
- Pregnancy. Both labels tell prescribers to stop the drug when a pregnancy is recognized, and both Medication Guides say to tell your healthcare provider if you become pregnant. Weight loss offers no benefit during pregnancy and may harm the baby.
- Breastfeeding. The Foundayo Medication Guide says breastfeeding is not recommended during treatment.
- Liver disease. Foundayo is not recommended for severe liver impairment (Child-Pugh Class C).
- Surgery. Tell every provider you take either drug before a procedure with anesthesia.
| Symptom | What the Medication Guides say |
|---|---|
| Severe stomach pain that will not go away, with or without nausea or vomiting | Stop the medicine and call your healthcare provider right away (possible pancreatitis) |
| Swelling of the face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; very rapid heartbeat | Stop the medicine and get medical help right away (possible serious allergic reaction) |
| Stomach problems that are severe or will not go away | Tell your healthcare provider (severe stomach problems) |
| Nausea, vomiting, or diarrhea that does not go away | Tell your healthcare provider right away (risk of dehydration and kidney problems) |
| Upper stomach pain, fever, yellow skin or eyes, clay-colored stools | Tell your healthcare provider right away (possible gallbladder problems) |
| A lump or swelling in the neck, hoarseness, trouble swallowing, shortness of breath | Tell your healthcare provider (possible thyroid tumor) |
| Changes in vision, if you have type 2 diabetes | Tell your healthcare provider |
| Dizziness, sweating, shakiness, confusion, or fast heartbeat while also taking insulin or a sulfonylurea | Possible low blood sugar: before starting, talk to your healthcare provider about how to manage it |
If you take too much of either medicine, both Medication Guides say to call your healthcare provider or Poison Help at 1-800-222-1222, or go to the nearest hospital emergency room right away.
Foundayo vs Zepbound Cost and Insurance
In Foundayo vs Zepbound pricing, Foundayo starts lower. Lilly's self-pay price for Foundayo starts at $149 a month for the lowest dose, and for Zepbound at $299 a month for the 2.5 mg dose. Both cost more at higher doses.
Lilly announced the Foundayo starting price at approval in April 2026. It announced the Zepbound starting price in February 2026, the same for the KwikPen and the single-dose vial. NPR reported that higher doses of both cost more.
Prices for each dose can change, so check LillyDirect or your pharmacy before you decide. Prices checked September 24, 2026. For every Foundayo dose price, the savings card limits, and the Medicare rules, see our orforglipron price guide. For Zepbound savings cards and the Medicare GLP-1 Bridge, see our Zepbound coupon guide.
What changes the price:
- Dose. Both drugs cost more as the dose goes up, so the starting price is not the price you will pay for the whole course.
- Commercial insurance. Eligible people with commercial insurance that covers Foundayo may pay as little as $25 a month with the Foundayo savings card, according to Lilly.
- Medicare. The Medicare GLP-1 Bridge runs from July 1, 2026, to December 31, 2027, with a $50 copay for eligible beneficiaries. The Part D deductible does not apply, and the copay does not count toward out-of-pocket costs (CMS).
- Which forms Medicare covers. According to the CMS prior authorization form, the Bridge covers Foundayo tablets but only the KwikPen form of Zepbound, and your prescriber must submit a prior authorization.
Will Zepbound get cheaper? We do not forecast prices. The facts above are current as of September 24, 2026, and coverage rules vary by plan.
Eating Well on Foundayo or Zepbound
Foundayo and Zepbound both reduce appetite, so eating enough protein and nutrients matters on either one. Both labels report greater fat loss than lean mass loss, which means some lean mass is lost too.
This is general nutrition advice, not label guidance. A 2025 joint nutrition advisory from four obesity and nutrition groups notes that 1.2 to 1.6 grams of protein per kilogram of body weight per day have been proposed during active weight loss, though the right body weight to use is unsettled. It adds that strength (resistance) training helps preserve muscle during weight loss.
Simple habits that help on a smaller appetite:
- Protein first. Start meals with eggs, fish, chicken, tofu, beans, or Greek yogurt.
- Small plates, more often. Three small meals and one or two snacks can be easier than large portions.
- Fiber and fluids. Vegetables, oats, and steady water intake support digestion.
- Plan ahead. Keep easy high-protein foods on hand for low-appetite days.
If you want high-protein recipes and meal ideas sized for a smaller appetite, see our GLP-1 meal plan and protein guide.
Which One Might Fit You?
Neither Foundayo nor Zepbound is better for everyone. The right choice depends on your goals, health, other medicines, and coverage, and your prescriber makes it with you. The factors below come from the two labels and the trial data above.
| Factor | Foundayo | Zepbound |
|---|---|---|
| Needles | You prefer a daily tablet | A weekly shot is fine |
| Trial weight loss | Smaller: 11.1% at the top dose in ATTAIN-1 | Larger: 20.9% at the top dose in SURMOUNT-1 |
| Sleep apnea | Not approved for it | Approved for moderate to severe OSA with obesity |
| Other medicines | Check strong CYP3A4 drugs and simvastatin above 20 mg first | Label notes cover insulin, sulfonylureas, and oral medicines, as with Foundayo |
| Birth control pills | Non-oral method or added barrier method for 30 days after starting and after each dose increase | Non-oral method or added barrier method for 4 weeks after starting and after each dose increase |
| Liver disease | Not recommended in severe impairment (Child-Pugh Class C) | No dose change recommended for liver impairment (label) |
| Travel and storage | Room temperature | Refrigerator, with limited time at room temperature (rules differ by device) |
| Coverage | Lower self-pay start; Foundayo tablets covered by the Medicare Bridge | Only the KwikPen in the Medicare Bridge |
Foundayo is not the only GLP-1 pill. Wegovy also comes as a tablet (Wegovy label, revised 06/2026), and a full list of approved options can help you compare. Our page on how to take the Wegovy pill explains its morning routine.
Frequently Asked Questions
Is Foundayo as effective as Zepbound?
In separate 72-week trials, the top Foundayo dose lowered weight by 11.1% on average and the top Zepbound dose by 20.9%. We found no head-to-head trial, so the results cannot be compared directly, but Zepbound's were larger.
Is Foundayo the same as tirzepatide?
No. Foundayo contains orforglipron, a different molecule that acts only on the GLP-1 receptor. There is no FDA-approved tirzepatide pill.
Can I switch from Zepbound to Foundayo?
Your prescriber decides. In the ATTAIN-MAINTAIN trial, people who moved from tirzepatide to orforglipron kept 74.7% of their weight loss on average after a year vs 49.2% on placebo, but neither label gives switching instructions.
Can you take Foundayo and Zepbound together?
No. Both labels say that using them with another GLP-1 receptor agonist is not recommended.
Do you have to take Foundayo on an empty stomach or with water?
No. The label says to take one tablet by mouth once daily, with or without food, swallowed whole. It sets no water, fasting, or time-of-day rule.
Is Foundayo cheaper than Zepbound?
At the starting doses, yes. Lilly's self-pay price starts at $149 a month for the lowest Foundayo dose and $299 for Zepbound 2.5 mg, and both cost more at higher doses. Prices were checked on September 24, 2026.
Does Foundayo cause more nausea than Zepbound?
Nausea rates look similar in the two labels (26% to 35% vs 25% to 29%), while vomiting looks higher with Foundayo (13% to 24% vs 8% to 13%). The numbers come from separate trials and cannot be compared directly.
Is Foundayo approved for sleep apnea?
No. Foundayo is approved only for weight reduction and long-term weight maintenance in adults. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity.
Conclusion
Foundayo vs Zepbound is a trade between convenience and size of effect. Foundayo is a daily tablet with no food rules and a lower starting price. Zepbound is a weekly shot that produced about twice the placebo-adjusted weight loss in its own trials and also treats sleep apnea.
- Not the same drug. Foundayo is orforglipron; there is no FDA-approved tirzepatide pill.
- Not head-to-head. The weight-loss gap comes from separate trials.
- Similar side effects. Both mainly cause stomach and gut symptoms during dose increases.
- Switching is a prescriber decision. In one trial, people kept most but not all of their weight loss on average after moving to orforglipron.
Whichever medicine you and your prescriber choose, protein-first meals help you get the most from a smaller appetite, and our GLP-1 meal plan and protein guide can make that easier.
References
- Foundayo (orforglipron) Prescribing Information and Medication Guide, revised 07/2026: U.S. Food and Drug Administration
- Approval letter, NDA 220934 (Foundayo), April 1, 2026: U.S. Food and Drug Administration
- Drugs@FDA overview, NDA 220934: U.S. Food and Drug Administration
- Zepbound (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
- Zepbound Medication Guide, revised 08/2026: Eli Lilly
- Wharton S et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med, 2025
- Horn DB et al. Orforglipron for obesity in people with type 2 diabetes (ATTAIN-2). Lancet, 2025
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med, 2022
- Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med, 2026
- ClinicalTrials.gov search: orforglipron and tirzepatide, run September 24, 2026
- openFDA drug approvals database, tirzepatide: U.S. Food and Drug Administration
- FDA's concerns with unapproved GLP-1 drugs used for weight loss: U.S. Food and Drug Administration
- Medicare GLP-1 Bridge: Centers for Medicare and Medicaid Services
- Medicare GLP-1 Bridge prior authorization form: Centers for Medicare and Medicaid Services
- FDA approves Lilly's Foundayo (orforglipron): Eli Lilly news release, April 1, 2026
- Foundayo (orforglipron) now available in the U.S.: Eli Lilly news release, April 9, 2026
- Zepbound (tirzepatide) now available in multi-dose KwikPen: Eli Lilly news release, February 23, 2026
- The FDA approves a new obesity pill: NPR, April 1, 2026
- Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA, and TOS, 2025
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med, 2025
- Wegovy (semaglutide) injection and tablets Prescribing Information, revised 06/2026: Novo Nordisk
This article is for education only and is not medical advice. It summarizes the FDA labels and published research and gives no personalized dosing advice. Talk to your prescriber before starting, stopping, or switching any weight-loss medicine. Read our full medical disclaimer.